Oppenheimer Appoints Chris DeFalco And John Hyland As Co-Heads Of Equity Capital Markets Accessibility StatementSkip Navigation Peter Bennett to Lead Corporate Executive Services Team In their new roles, they will jointly oversee the strategic direction, execution, and continued growth of Oppenheimer's leading equity capital markets platform, with a focus on deepening Oppenheimer's product expertise across its core industry verticals. Both will also serve on the firm's Investment Banking Commitment Committe ...

Core Viewpoint - Oppenheimer & Co. Inc. has appointed Eric Nortman as Managing Director and Head of Debt Private Placements, aiming to enhance its financing solutions for investment banking clients [2][3]. Group 1: Leadership and Structure - Eric Nortman will lead the newly established Debt Private Placements Group, focusing on raising capital through the private credit market [4]. - Nortman will report to Rob Lowenthal and Gilbert Dychiao, Co-Heads of Investment Banking at Oppenheimer [3]. Group 2: Market Demand and Strategy - There is a growing demand for flexible, non-dilutive, and relationship-driven capital solutions, which the new group aims to address [5]. - The Debt Private Placements Group will collaborate with the Fixed Income division to execute private debt transactions and strengthen relationships with issuers and investors [4]. Group 3: Eric Nortman's Background - Nortman has over 20 years of experience in private credit, debt capital markets, and leveraged finance, previously serving as Managing Director at Blue Torch Capital [5]. - His career includes significant roles at Blackstone and Medley Management, where he focused on sourcing, structuring, and underwriting credit investments [6]. Group 4: Company Vision - Oppenheimer aims to connect clients with sophisticated private debt investors and provide the execution needed for complex transactions [7]. - The firm emphasizes the importance of deep knowledge and experience in private debt to enhance the solutions offered to clients [6].

Core Viewpoint - Guardian Pharmacy Services, Inc. is actively participating in key industry conferences to enhance visibility and communicate its growth trajectory and financial outlook for 2026 [1]. Group 1: Conference Participation - Guardian Pharmacy Services will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026, featuring a fireside chat with the CEO and CFO [1]. - The company will also present at the Raymond James Institutional Investors Conference in Orlando, Florida, on March 2, 2026 [1]. Group 2: Financial Performance and Outlook - Guardian Pharmacy Services is set to release its fourth quarter and full-year 2025 financial results on March 11, 2026, followed by a conference call to discuss these results [1]. - The company is reiterating its 2025 guidance and providing a preliminary financial outlook for 2026, expecting low double-digit adjusted EBITDA growth supported by its operating model and anticipated drug pricing changes [1].

Client Assets and Management - As of December 31, 2025, Oppenheimer Holdings Inc. held client assets under administration of $143.3 billion[12] - The Company had $55.2 billion of client assets under management in fee-based programs[17] - Oppenheimer's Trust Company held custodial assets of $615.1 million as of December 31, 2025[51] Investment Banking and Capital Markets - Oppenheimer employs over 200 investment banking professionals across the United States, the United Kingdom, and Israel[25] - The investment banking division focuses on sectors including Consumer and Retail, Financial Institutions, Healthcare, Industrials, Energy, and Technology[25] - Oppenheimer provides a full range of equity capital raising solutions, acting as a leading underwriter for mid- and small-cap equity offerings[27] - The Company offers debt capital markets solutions for domestic and international companies, including structuring and distributing public and private debt[28] - Oppenheimer's public finance group assists clients in raising capital for state and local governments, public agencies, and private developers[29] - The Company provides alternative investment firms with a range of value-added services, including fundraising advisory and direct transactions[31] Research and Trading - Oppenheimer employs 36 senior research analysts covering approximately 675 equity securities[32] - The firm provides a combination of high touch and low touch equity execution strategies tailored for institutional clients[38] - Oppenheimer's fixed income research team consists of 11 professionals focusing on high yield corporate, mortgage-backed, and Emerging Market securities[44] - The company has a dedicated team for event-driven trading strategies, including risk/merger arbitrage and SPAC valuation[37] - Oppenheimer's proprietary trading activities expose its capital to market value fluctuations, as it acts as a market maker[45] - The firm has a multi-currency platform enabling client trades in securities denominated in foreign currencies[59] Human Capital and Employee Development - Oppenheimer employs 2,947 employees, including 924 financial advisors, highlighting the importance of human capital in delivering services[62] - The company emphasizes a values-based culture to attract and retain high-quality financial advisors, supporting their professional development[67] - The Company offers a variety of professional development programs, including the Summer Internship Program and the Financial Advisor Training Program, aimed at enhancing employee skills[68] - Oppenheimer University provides an extensive e-Learning platform with courses covering compliance, cybersecurity, and industry topics to support employee development[69] - Oppenheimer's human capital management strategy is overseen by the Management Committee in collaboration with the President/CEO[61] Financial Performance and Compensation - The Company's compensation as a percentage of revenue for 2025 is 62.1%, down from 65.4% in 2024 and 62.7% in 2023[74] - Wealth Management compensation as a percentage of revenue is 52.1% for 2025, compared to 52.9% in 2024 and 47.6% in 2023[74] - Capital Markets compensation as a percentage of revenue is 60.9% for 2025, significantly reduced from 72.3% in 2024 and 77.9% in 2023[74] Regulatory Compliance and Challenges - Oppenheimer is subject to extensive regulation by the SEC and FINRA, impacting its operational methods and profitability[82] - The Company has implemented measures to comply with the Bank Secrecy Act and the USA PATRIOT Act, which include risk-based programs to prevent money laundering[87] - The Sarbanes-Oxley Act requires the Company to maintain effective internal controls over financial reporting, which has been confirmed as effective as of December 31, 2025[88] - The Company faces intense competition from various financial service providers, including fintech firms offering lower-cost services, but has not seen a significant impact on its business[76] - The Company is subject to net capital requirements under Rule 15c3-1, requiring a minimum net capital of at least 2% of aggregate debit items or $1.5 million, whichever is greater[104] - As of December 31, 2025, the Company was in compliance with its regulatory capital requirements[107] - Oppenheimer Trust is required to maintain capital of $4.15 million and was in compliance as of December 31, 2025[110] - Oppenheimer Europe Ltd. must maintain a minimum of £750,000 in capital and was compliant as of December 31, 2025[108] - Oppenheimer Investments Asia Limited is required to maintain a minimum of HKD 3.0 million or 5% of adjusted liabilities, and was compliant as of December 31, 2025[109] Compliance Costs and Regulatory Changes - The Company has faced increased compliance costs due to the implementation of Regulation Best Interest (Reg BI) and ongoing training requirements[92] - The SEC adopted amendments to Regulation S-P, effective December 2025, requiring incident response programs for unauthorized access to customer information[98] - The SEC approved the Consolidated Audit Trail (CAT) to monitor U.S. securities transactions, with Oppenheimer beginning reporting in June 2020[102] - Compliance with CAT requirements has been costly and presents potential privacy issues for the company[102] - MiFID II, effective January 3, 2018, has negatively impacted commission revenue for equity research and market liquidity in Europe[91] - The final prohibited transaction exemption (PTE) compliance date was February 1, 2022, requiring additional processes beyond Reg BI compliance[93] - The DOL proposed a Retirement Security Rule package on October 31, 2023, which could broaden the fiduciary standard for client relationships[94] - The California Consumer Privacy Act (CCPA) and its amendments require specific privacy disclosures and consumer rights regarding personal information[96] - The General Data Protection Regulation (GDPR) imposes strict compliance requirements for companies processing personal data of EU residents[97]

Core Insights - Oppenheimer & Co. Inc. has appointed Vien Le as Managing Director in its Public Finance Investment Banking Group, based in Los Angeles [1][2] - Le brings over 20 years of municipal finance experience, focusing on California and supporting clients in the West, including Oregon and Washington [2][3] - The addition of Le is expected to enhance Oppenheimer's capabilities and momentum in the public finance sector on the West Coast [3][5] Company Overview - Oppenheimer Holdings Inc. provides a comprehensive range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions [5]

Core Viewpoint - Corvus Pharmaceuticals is actively engaging with investors through one-on-one meetings and a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its focus on immunotherapy and clinical development [1][2]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in ITK inhibition as a novel approach to immunotherapy for various immune diseases and cancers [3]. - The company's lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL and a Phase 1 clinical trial for atopic dermatitis [3]. Upcoming Events - The corporate presentation will take place virtually on February 26, 2026, at 2:40 PM ET, with a live webcast available for 90 days post-event [1][2].

Core Insights - Oppenheimer analysts have conducted positive channel checks for CrowdStrike and SentinelOne, indicating strong performance in the cybersecurity sector [1][2]. CrowdStrike - CrowdStrike remains a leader in next-generation endpoint security, with accelerating revenue growth in fiscal 2026 following a significant IT outage in summer 2024 [4]. - The company has received the best sentiment from VAR partners, who have revised their expectations positively, highlighting CrowdStrike's success in replacing legacy vendors and effective cross-selling [5]. - The introduction of the Falcon Flex licensing model has been a key driver of success, allowing customers to access the full product portfolio while only paying for needed modules [7]. - CrowdStrike's stock is trading at a forward price-to-sales (P/S) multiple of approximately 18 times analysts' estimates for the next fiscal year [8]. SentinelOne - SentinelOne is considered one of the cheapest endpoint security providers, trading at a forward P/E of below 4 times next fiscal year estimates, while experiencing rapid revenue growth with a 23% increase in both revenue and annualized recurring revenue (ARR) in fiscal Q3 [9]. - Oppenheimer's channel checks indicate significant improvements for SentinelOne, with most VARs exceeding their plans for 2025 and reporting high-20% growth for the calendar year [11]. - SentinelOne's Purple AI has been recognized as the best autonomous security operations center (SOC) solution, outperforming competitors like CrowdStrike's Charlotte AI [11]. - Given its strong technology and revenue growth, SentinelOne is viewed as one of the most underpriced stocks in the market, with potential for significant upside [12].

Group 1 - Kiora Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 p.m. ET, with a live webcast available on their investor relations website [1] - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [2] - The company is developing KIO-104 for retinal inflammation and KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, with the latter being a molecular photoswitch aimed at restoring vision [2] Group 2 - Kiora Pharmaceuticals encourages investors to follow their updates on social media platforms like X and LinkedIn, as well as to visit their website for relevant information [3]

Core Viewpoint - Aldeyra Therapeutics, Inc. is focused on developing innovative therapies for immune-mediated diseases and will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Participation - Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will engage in a virtual fireside chat at the conference [1] - The discussion will be moderated by Andreas Argyrides, Managing Director, Senior Biotech [1]

Core Insights - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases [1] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with a webcast available for 90 days post-event [1] Company Overview - Q32 Bio targets potent regulators of the adaptive immune system to develop innovative therapies for alopecia areata and other autoimmune and inflammatory diseases [1] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [1] Product Development - Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody, currently in a Phase 2 program for treating alopecia areata [1] - The IL-7 and TSLP pathways are implicated in various T cell-mediated autoimmune diseases, highlighting the potential of Q32 Bio's therapeutic approach [1]